195 related articles for article (PubMed ID: 36522531)
1. Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.
Fang B; Wei Y; Zeng H; Li Y; Chen S; Zhang T; Pan J; Wang B; Wu J; Jin S; Gan H; Hu M; Zhang D; Ye D; Zhu Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1541-1551. PubMed ID: 36522531
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
3. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer.
Li J; Hu H; Qin G; Bai F; Wu X; Ke H; Zhang J; Xie Y; Wu Z; Fu Y; Zheng H; Gong L; Xie Z; Deng Y
Clin Cancer Res; 2024 Jan; 30(2):368-378. PubMed ID: 37906636
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
[TBL] [Abstract][Full Text] [Related]
9. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
11. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.
Rosty C; Walsh MD; Lindor NM; Thibodeau SN; Mundt E; Gallinger S; Aronson M; Pollett A; Baron JA; Pearson S; Clendenning M; Walters RJ; Nagler BN; Crawford WJ; Young JP; Winship I; Win AK; Hopper JL; Jenkins MA; Buchanan DD
Fam Cancer; 2014 Dec; 13(4):573-82. PubMed ID: 25117503
[TBL] [Abstract][Full Text] [Related]
13. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
14. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.
Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y
BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440
[TBL] [Abstract][Full Text] [Related]
15. DNA mismatch repair in cancer.
Baretti M; Le DT
Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
[TBL] [Abstract][Full Text] [Related]
16. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
[TBL] [Abstract][Full Text] [Related]
17. Hereditary prostate cancer as a feature of Lynch syndrome.
Bauer CM; Ray AM; Halstead-Nussloch BA; Dekker RG; Raymond VM; Gruber SB; Cooney KA
Fam Cancer; 2011 Mar; 10(1):37-42. PubMed ID: 20872076
[TBL] [Abstract][Full Text] [Related]
18. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
19. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer.
Li J; Wu C; Hu H; Qin G; Wu X; Bai F; Zhang J; Cai Y; Huang Y; Wang C; Yang J; Luan Y; Jiang Z; Ling J; Wu Z; Chen Y; Xie Z; Deng Y
Cancer Cell; 2023 Jun; 41(6):1152-1169.e7. PubMed ID: 37172580
[TBL] [Abstract][Full Text] [Related]
20. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
